Tests two bone-strengthening drugs in women with postmenopausal osteoporosis
Compares two approved drug treatments for weak bones in postmenopausal women.
Plain-language title generated from the registry record
Registry title: Combined Anabolic Therapy
Key facts
- Where
- Boston, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Massachusetts General HospitalBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Massachusetts General Hospital
- Trial code
- NCT06558188
- Record updated
- 8 October 2026
- Original description
In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.Read full original descriptionShow less
Combined Anabolic Therapy Study
In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.
Inclusion: women aged 45+; postmenopausal; osteoporotic with high risk of fracture.
Exclusion: no significant previous use of bone health modifying treatments; known congenital or acquired bone disease other than osteoporosis; significant renal disease, liver disease, cardiopulmonary disease, or psychiatric disease; history of malignancy (except non-melanoma skin carcinoma); abnormal calcium or parathyroid hormone level; serum vitamin D <20 ng/dL; anemia (hematocrit <32%); excessive alcohol use or substance abuse; known contraindications to romosozumab or teriparatide.